Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 12 month target prices for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they anticipate the company's share price to reach $65.88 in the next year. This suggests a possible upside of 26.1% from the stock's current price.
View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts.

Enanta Pharmaceuticals' stock was trading at $46.52 at the start of the year. Since then, ENTA stock has increased by 12.3% and is now trading at $52.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our ENTA earnings forecast.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings data on Monday, November, 21st. The biotechnology company reported ($1.27) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.10. The biotechnology company had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative trailing twelve-month return on equity of 34.73%. The company's revenue was down 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.22) earnings per share.

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.25%), Hennion & Walsh Asset Management Inc. (0.15%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.05%), Inspire Investing LLC (0.02%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $52.24.

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.09 billion and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.91) on an earnings per share basis.

The company employs 155 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.